Athena Athena

X
[{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bacainn Therapeutics Announces IND Clearance for BT051 and Initiation of Phase 1 Clinical Trial","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"June 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"December 2020","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"},{"orgOrder":0,"company":"Bacainn Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Bacainn Therapeutics Presents Data on BT051 at ECCO \u201821","therapeuticArea":"Gastroenterology","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"July 2021","url1":"","url2":"","graph1":"Gastroenterology","graph2":"Phase I"}]

Find Clinical Drug Pipeline Developments & Deals by Bacainn Therapeutics

Menu
Loading...
Filters Filter
×
FILTER:
filter Company
    filter Sponsor
      filter Country
        filter Therapeutic Area
          filter Study Phase

            Active Filter(s):

            Companies By Therapeutic Area

            Development Status

            Details:

            BT051 is an oral, locally-acting inhibitor of neutrophil trafficking and activation and is in clinical development for the treatment of inflammatory bowel disease (IBD), which impacts as many as 6.8 million people in the United States and Europe.

            Lead Product(s): BT051

            Therapeutic Area: Gastroenterology Product Name: BT051

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable July 09, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Single doses of BT051 up to 3500 mg were generally safe and well tolerated in all healthy subjects exposed. Bacainn Therapeutics plans to initiate a Phase 1b clinical trial of BT051 in patients with moderate to severe active ulcerative colitis, based on the study results.

            Lead Product(s): BT051

            Therapeutic Area: Gastroenterology Product Name: BT051

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable December 02, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            The Phase 1 clinical trial is evaluating various dose levels of BT051 for safety, tolerability and pharmacokinetics in a double-blind, placebo-controlled study in healthy volunteers.

            Lead Product(s): BT051

            Therapeutic Area: Gastroenterology Product Name: Undisclosed

            Highest Development Status: Phase I Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable June 10, 2020

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY